Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.50    -0.01 (-0.66%)
Bid:
1.50
Ask:
1.88
Spread: 0.38 (25.333%)
Market Cap: £5.26m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

Director's Dealing

25 Jul 2007 12:03

Proteome Sciences Plc ("Proteome Sciences" or "the Company")

DIRECTOR'S DEALING

Proteome Sciences announces that it has received notification today from James Malthouse, an Executive Director of the Company, that 50,000 ordinary shares that were held in his late wife's name have been transferred for a nil consideration to his adult daughter. As a consequence of this, the shares no longer form part of his beneficial holdings as defined by the AIM rules.

James Malthouse now has an interest in 250,000 Ordinary Shares of the issued ordinary share capital of the Company.

Enquiries Proteome Sciences plc

Christopher Pearce, Chief Executive Officer

Email: christopher.pearce@proteomics.com

James Malthouse, Finance Director

Email: james.malthouse@proteomics.com

Tel: +44 (0)1932 865065

Public Relations for Proteome Sciences

IKON AssociatesAdrian Shaw Tel: +44 (0)1483 535102Mobile: +44 (0)797 9900733Email: adrian@ikonassociates.com Coast CommunicationsMatt BaldwinTel: +44 (0) 1233 503200Mobile: +44 (0) 7930 439739

Email: matt@coastcommunications.com

PROTEOME SCIENCES PLC
Date   Source Headline
20th Aug 20127:00 amRNSRe Agreement
29th Jun 201212:10 pmRNSAGM Statement
7th Jun 20123:10 pmRNSAnnual Financial Report
29th May 20127:00 amRNSFinal Results
30th Apr 20127:00 amRNSTotal Voting Rights
5th Apr 20127:00 amRNSStroke biomarker license to Randox
29th Mar 20125:11 pmRNSBlock Admission Return
28th Mar 20127:00 amRNSCompletion of Alzheimer's Plasma Biomarker Study
19th Mar 201210:00 amRNSEuroHYP EU Grant Award for Stroke
8th Mar 20128:55 amRNSHolding(s) in Company
5th Mar 20127:00 amRNSChange of Adviser
24th Feb 20124:24 pmRNSDirector/PDMR Shareholding
31st Jan 20127:00 amRNSTotal Voting Rights
18th Jan 20127:00 amRNSAdditional Listing
22nd Dec 20117:00 amRNSPromising hits against Alzheimer's Target
24th Nov 20117:00 amRNSNovel In Vitro Assays Developed
8th Nov 20113:39 pmRNSDirector Holdings
7th Oct 20117:00 amRNSBlock Admission Return
30th Sep 20117:00 amRNSInterim Results 2011
11th Aug 20114:35 pmRNSPrice Monitoring Extension
11th Aug 20111:33 pmRNSNotification of Major interest in Shares
9th Aug 20117:00 amRNSProteome Sciences as Preferred Supplier
26th Jul 20117:00 amRNSAppointment of VP Business Development
14th Jul 20117:00 amRNSCollaboration with Buck Institute - biomarket test
7th Jul 20117:00 amRNSCollaboration Agreement
29th Jun 20111:31 pmRNSAGM Statement
28th Jun 20118:12 amRNSDenamic ?6.9m EU Framework Grant
6th Jun 20111:21 pmRNSAnnual Financial Report
27th May 20117:00 amRNSFinal Results
27th May 20117:00 amRNSFinal Results
29th Mar 20117:00 amRNSTakeda Research Contract
28th Mar 20114:38 pmRNSBlocklisting Interim Review
8th Mar 20114:40 pmRNSSecond Price Monitoring Extn
8th Mar 20114:35 pmRNSPrice Monitoring Extension
31st Jan 20117:00 amRNSContract for Biomarker Services with Eisai
10th Jan 20113:39 pmRNSDirector/PDMR Shareholding
23rd Dec 20107:00 amRNSDirectorate Change
20th Dec 20107:00 amRNSResearch Contract
30th Nov 20107:00 amRNSTrading Statement
23rd Nov 201010:30 amRNSBlocklisting Interim Review
23rd Nov 20109:46 amRNSHolding(s) in Company
15th Nov 20107:00 amRNSProteome Sciences form alliance with ICON
14th Oct 20103:00 pmRNSHolding(s) in Company
30th Sep 20107:00 amRNSHalf Yearly Report
28th Sep 20107:00 amRNSStatement re Warranty Claim
23rd Sep 20107:00 amRNSCollaboration with Thermo Fisher
21st Jul 20104:26 pmRNSHolding(s) in Company
13th Jul 20107:00 amRNSProduct Launch
6th Jul 20101:11 pmRNSDirector/PDMR Shareholding
1st Jul 201011:10 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.